WO2023034568A1 - Specific therapeutic medical marijuana doses for stress and pain - Google Patents
Specific therapeutic medical marijuana doses for stress and pain Download PDFInfo
- Publication number
- WO2023034568A1 WO2023034568A1 PCT/US2022/042454 US2022042454W WO2023034568A1 WO 2023034568 A1 WO2023034568 A1 WO 2023034568A1 US 2022042454 W US2022042454 W US 2022042454W WO 2023034568 A1 WO2023034568 A1 WO 2023034568A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cbd
- thc
- pain
- pharmaceutical composition
- subject
- Prior art date
Links
- 208000002193 Pain Diseases 0.000 title claims abstract description 20
- 230000001225 therapeutic effect Effects 0.000 title description 4
- 244000025254 Cannabis sativa Species 0.000 title description 3
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 title description 3
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 title description 3
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims abstract description 78
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims abstract description 78
- 229950011318 cannabidiol Drugs 0.000 claims abstract description 78
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims abstract description 78
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims abstract description 78
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims abstract description 73
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims abstract description 73
- 229960004242 dronabinol Drugs 0.000 claims abstract description 73
- 238000000034 method Methods 0.000 claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 31
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 8
- 230000036506 anxiety Effects 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 150000001875 compounds Chemical class 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 15
- 239000000203 mixture Substances 0.000 description 10
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 241000218236 Cannabis Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 208000000094 Chronic Pain Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940124583 pain medication Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000026251 Opioid-Related disease Diseases 0.000 description 2
- 101000972349 Phytolacca americana Lectin-A Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
Definitions
- the invention provides a method of treating pain in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio between about 3: 1 and about 6: 1 CBD: THC.
- CBD cannabidiol
- THC tetrahydrocannabinol
- the invention provides a method of treating anxiety in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio between about 3: 1 and about 6: 1 CBD: THC.
- CBD cannabidiol
- THC tetrahydrocannabinol
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio of about 4: 1 or about 3: 1 CBD: THC.
- CBD cannabidiol
- THC tetrahydrocannabinol
- the ratio is about 4: 1 or about 3 : 1 CBD:THC.
- the pharmaceutical composition comprises 100 mg CBD + 30 mg THC.
- the pharmaceutical composition comprises 40 mg CBD + 10 mg THC.
- the subject is a human.
- FIGS. 1 A-1B Plasma levels of CBD and THC - adjusted for baseline, for each of the dose conditions over the course of 4.45 hours (285 minutes).
- FIG. 1 A Relative to placebo, plasma CBD levels significantly increased for the CBD100 (p ⁇ 0005), CBD40+THC10 (p ⁇ 01), and for CBD100+THC30 (p ⁇ 0001) but not for CBD40 alone (p ⁇ 34) or CBD40+THC20 (p ⁇ 07).
- FIG. IB Relative to placebo, plasma THC levels significantly increased for the CBD40+THC20 (p ⁇ 01) and for CBD100+THC30 (p ⁇ 0001) but not for CBD40 alone (p ⁇ 89) or CBD100 alone (p ⁇ 76) or CBD40+THC10 (p ⁇ 14).
- FIGS. 2A-2D Blood Pressure, Pulse and Wanting More Drug Rating, adjusted for Baseline.
- FIG. 2A Relative to placebo, average systolic blood pressure (BP) adjusted for baseline was significantly decreased in the CBD40/THC10 (p ⁇ 01 ) and the CBD100/THC30 doses (p ⁇ 001), but not for other doses.
- FIG. 2B Relative to placebo, diastolic BP adjusted for baseline was significantly increased for the CBD 100 dose (p ⁇ 05) but not for any other dose.
- FIG.. 2C Relative to placebo, average pulse adjusted for baseline decreased for all doses non- significantly, and was significantly increased by an average of 2bpm for the CBD100+THC30 dose (p ⁇ 001).
- FIG. 2A Relative to placebo, average systolic blood pressure (BP) adjusted for baseline was significantly decreased in the CBD40/THC10 (p ⁇ 01 ) and the CBD100/THC30 doses (p ⁇ 001), but not for other doses
- 2D Relative to placebo, average drug craving (want more drug) was significantly reduced for all doses including CBD40 (p ⁇ 001), CBD100 (p ⁇ 001), CBD40+THC10 (p ⁇ 05), CBD40+THC20 (p ⁇ 01) and CBD100+THC30 (p ⁇ 001).
- FIGS. 3A-3B Provoked average pain and anxiety (adjusted for baseline) ratings during adapted CPT protocol.
- FIG. 3 A Relative to placebo, average provoked pain ratings were significant decreased in the CBD40/THC10 and in the CBD10/THC30 doses (p’s ⁇ 05), but not for other doses.
- FIG. 3B Relative to placebo, average adjusted anxiety ratings were only significant reduced in the CBD100/THC30 dose (p ⁇ 01 ) and not for any other dose.
- an element means one element or more than one element.
- “About” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ⁇ 20% or ⁇ 10%, more preferably ⁇ 5%, even more preferably ⁇ 1%, and still more preferably ⁇ 0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
- composition refers to a mixture of at least one compound useful within the invention with a pharmaceutically acceptable carrier.
- the pharmaceutical composition facilitates administration of the compound to a patient or subject. Multiple techniques of administering a compound exist in the art including, but not limited to, intravenous, subcutaneous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical administration.
- CBD canbidiol
- THC tetrahydrocannabinol
- tetrahydrocannabinol refers to the molecule having the formula: and pharmaceutically acceptable salts thereof.
- an “effective amount” or “therapeutically effective amount” of a compound is that amount of compound that is sufficient to provide a beneficial effect to the subject to which the compound is administered.
- An “effective amount” of a delivery vehicle is that amount sufficient to effectively bind or deliver a compound.
- patient refers to any animal, or cells thereof whether in vitro or in situ, amenable to the methods described herein.
- the patient, subject or individual is a human.
- the term “pharmaceutically acceptable” refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively non-toxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
- the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the invention within or to the patient such that it may perform its intended function.
- a pharmaceutically acceptable material, composition or carrier such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the invention within or to the patient such that it may perform its intended function.
- Such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body.
- Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, including the compound useful within the invention, and not injurious to the patient.
- materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic s
- “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound useful within the invention, and are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the compositions.
- the “pharmaceutically acceptable carrier” may further include a pharmaceutically acceptable salt of the compound useful within the invention.
- Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the invention are known in the art and described, for example in Remington’s Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.
- treating a disease or disorder means reducing the frequency with which a symptom of the disease or disorder is experienced by a patient.
- Disease and disorder are used interchangeably herein.
- the term “treatment” or “treating” encompasses prophylaxis and/or therapy. Accordingly, the compositions and methods of the present invention are not limited to therapeutic applications and can be used in prophylactic ones. Therefore “treating” or “treatment” of a state, disorder or condition includes: (i) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a subject that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition, (ii) inhibiting the state, disorder or condition, i.e., arresting or reducing the development of the disease or at least one clinical or subclinical symptom thereof, or (iii) relieving the disease, i.e. causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
- ranges throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
- the invention provides a method of treating pain in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio between about 3: 1 and about 6: 1 CBD:THC. In various embodiments, the ratio is about 4: 1 or about 3 : 1 CBD:THC.
- the invention provides a method of treating anxiety in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio of about 4: 1 or about 3 : 1 CBD:THC.
- compositions comprising specific ratios of CBD to THC show heightened efficacy in the treatment of pain (FIG. 3 A) and anxiety (FIG. 3B) relative to compositions comprising other ratios of these compounds.
- the pharmaceutical composition comprises 100 mg CBD + 30 mg THC.
- the pharmaceutical composition comprises 40 mg CBD + 10 mg THC.
- subject is a mammal. In various embodiments, the subject is a human.
- the pharmaceutical composition is configured to be delivered as a nasal spray, orally, subcutaneously, parenterally, sublingually, as a lozenge or as a solid or liquid formulation.
- the invention provides a pharmaceutical composition
- a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio of about 4: 1 or about 3: 1 CBD:THC.
- CBD cannabidiol
- THC tetrahydrocannabinol
- the pharmaceutical composition comprises at least one pharmaceutically acceptable excipient.
- the first study was directed towards assessing safety of the THC and CBD doses in healthy, recreational cannabis users.
- the key novel and surprising aspect of this study was the specific combinations of CBD+THC that were found to be significant in reducing pain and stress responses.
- CBD alone (often thought of as pain reducing) was not as effective as a combination of CBD with low doses of THC in the 4: 1 and 3 : 1 range but not in the 2: 1 proportion range. So 100 CBD + 30 THC and the 40 CBD + 10 THC were significantly different that then 40 CBD + 20 THC and the 100 CBD alone and 40 CBD alone. This suggests that low amounts of THC may act synergistically to increase therapeutic efficacy for pain, but not at moderate (2:1) or higher amounts (1 : 1).
- the novel pain provocation experimental method allowed for detection of this effect within this first safety protocol assessment.
- OTD Opioid Use Disorder
- CBD and THC at the ratios taught herein will exhibit greater efficacy than these compounds administered alone or at other ratios.
- Embodiment 1 provides a method of treating pain in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio between about 3 : 1 and about 6: 1 CBD:THC.
- CBD cannabidiol
- THC tetrahydrocannabinol
- Embodiment 2 provides the method of embodiment 1, wherein the ratio is about 4: 1 or about 3: 1 CBD:THC.
- Embodiment 3 provides the method of embodiments 1-2, wherein the pharmaceutical composition comprises 100 mg CBD + 30 mg THC.
- Embodiment 4 provides the method of embodiments 1-3, wherein the pharmaceutical composition comprises 40 mg CBD + 10 mg THC.
- Embodiment 5 provides the method of embodiments 1-4, wherein the subject is a human.
- Embodiment 6 provides a method of treating anxiety in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio between about 3 : 1 and about 6: 1 CBD: THC.
- CBD cannabidiol
- THC tetrahydrocannabinol
- Embodiment 7 provides a method of embodiment 6, wherein the ratio is about 4: 1 or about 3: 1 CBD: THC.
- Embodiment 8 provides a method of embodiments 6-7, wherein the pharmaceutical composition comprises 100 mg CBD + 30 mg THC.
- Embodiment 9 provides a method of embodiments 6-8, wherein the pharmaceutical composition comprises 40 mg CBD + 10 mg THC.
- Embodiment 10 provides a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio of about 4: 1 or about 3: 1 CBD:THC.
- CBD cannabidiol
- THC tetrahydrocannabinol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
In various aspects and embodiments the invention provides a method of treating pain, stress and anxiety in a subject in need thereof, wherein the method comprises administering to the subject in need thereof a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio between about 3:1 and about 6:1 CBD:THC.
Description
TITLE OF THE INVENTION
SPECIFIC THERAPEUTIC MEDICAL MARIJUANA DOSES FOR STRESS AND PAIN
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 63/240,702, filed September 3, 2021, the disclosures of which is incorporated herein by reference in its entirety.
BACKGROUND OF THE INVENTION
Medical use of cannabis products has expanded rapidly in recent years. Common reasons for use are alleviation of pain and also for reducing stress. However, little systematic and rigorous work has been done to maximize the efficacy of these products for use in the treatment of pain and management of stress. There is a need in the art for such compositions and methods. The present disclosure addresses this need.
SUMMARY OF THE INVENTION
In one aspect, the invention provides a method of treating pain in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio between about 3: 1 and about 6: 1 CBD: THC.
In another aspect, the invention provides a method of treating anxiety in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio between about 3: 1 and about 6: 1 CBD: THC.
In yet another aspect, the invention provides a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio of about 4: 1 or about 3: 1 CBD: THC.
In various embodiments, the ratio is about 4: 1 or about 3 : 1 CBD:THC. In various embodiments, the pharmaceutical composition comprises 100 mg CBD + 30 mg THC. In various embodiments, the pharmaceutical composition comprises 40 mg CBD + 10 mg THC.
In various embodiments, the subject is a human.
BRIEF DESCRIPTION OF THE DRAWINGS
The following detailed description of preferred embodiments of the invention will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there are shown in the drawings embodiments which are presently preferred. It should be understood, however, that the invention is not limited to the precise arrangements and instrumentalities of the embodiments shown in the drawings.
FIGS. 1 A-1B: Plasma levels of CBD and THC - adjusted for baseline, for each of the dose conditions over the course of 4.45 hours (285 minutes). FIG. 1 A: Relative to placebo, plasma CBD levels significantly increased for the CBD100 (p< 0005), CBD40+THC10 (p< 01), and for CBD100+THC30 (p< 0001) but not for CBD40 alone (p< 34) or CBD40+THC20 (p< 07). FIG. IB: Relative to placebo, plasma THC levels significantly increased for the CBD40+THC20 (p< 01) and for CBD100+THC30 (p< 0001) but not for CBD40 alone (p< 89) or CBD100 alone (p< 76) or CBD40+THC10 (p< 14).
FIGS. 2A-2D: Blood Pressure, Pulse and Wanting More Drug Rating, adjusted for Baseline. FIG. 2A: Relative to placebo, average systolic blood pressure (BP) adjusted for baseline was significantly decreased in the CBD40/THC10 (p< 01 ) and the CBD100/THC30 doses (p< 001), but not for other doses. FIG. 2B: Relative to placebo, diastolic BP adjusted for baseline was significantly increased for the CBD 100 dose (p< 05) but not for any other dose. FIG.. 2C: Relative to placebo, average pulse adjusted for baseline decreased for all doses non- significantly, and was significantly increased by an average of 2bpm for the CBD100+THC30 dose (p< 001). FIG. 2D: Relative to placebo, average drug craving (want more drug) was significantly reduced for all doses including CBD40 (p< 001), CBD100 (p< 001), CBD40+THC10 (p< 05), CBD40+THC20 (p< 01) and CBD100+THC30 (p< 001).
FIGS. 3A-3B: Provoked average pain and anxiety (adjusted for baseline) ratings during adapted CPT protocol. FIG. 3 A: Relative to placebo, average provoked pain ratings were significant decreased in the CBD40/THC10 and in the CBD10/THC30 doses (p’s< 05), but not for other doses. FIG. 3B: Relative to placebo, average adjusted anxiety ratings were only significant reduced in the CBD100/THC30 dose (p< 01 ) and not for any other dose.
DETAILED DESCRIPTION
Definitions
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present invention, the preferred materials and methods are described herein. In describing and claiming the present invention, the following terminology will be used.
It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or more than one element.
"About" as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20% or ±10%, more preferably ±5%, even more preferably ±1%, and still more preferably ±0.1% from the specified value, as such variations are appropriate to perform the disclosed methods.
As used herein, the term “composition” or “pharmaceutical composition” refers to a mixture of at least one compound useful within the invention with a pharmaceutically acceptable carrier. The pharmaceutical composition facilitates administration of the compound to a patient or subject. Multiple techniques of administering a compound exist in the art including, but not limited to, intravenous, subcutaneous, oral, aerosol, parenteral, ophthalmic, pulmonary and topical administration.
As used herein, the term “CBD” or “cannabidiol” refers to the molecule having the formula:
pharmaceutically acceptable salts thereof.
As used herein, the term “THC” or “tetrahydrocannabinol refers to the molecule having the formula:
and pharmaceutically acceptable salts thereof.
An “effective amount” or “therapeutically effective amount” of a compound is that amount of compound that is sufficient to provide a beneficial effect to the subject to which the compound is administered. An “effective amount” of a delivery vehicle is that amount sufficient to effectively bind or deliver a compound.
The terms "patient," "subject," "individual," and the like are used interchangeably herein, and refer to any animal, or cells thereof whether in vitro or in situ, amenable to the methods described herein. In certain non-limiting embodiments, the patient, subject or individual is a human.
As used herein, the term “pharmaceutically acceptable” refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively non-toxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler,
stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound useful within the invention within or to the patient such that it may perform its intended function. Typically, such constructs are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, including the compound useful within the invention, and not injurious to the patient. Some examples of materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline; Ringer’s solution; ethyl alcohol; phosphate buffer solutions; and other nontoxic compatible substances employed in pharmaceutical formulations. As used herein, “pharmaceutically acceptable carrier” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound useful within the invention, and are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the compositions. The “pharmaceutically acceptable carrier” may further include a pharmaceutically acceptable salt of the compound useful within the invention. Other additional ingredients that may be included in the pharmaceutical compositions used in the practice of the invention are known in the art and described, for example in Remington’s Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985, Easton, PA), which is incorporated herein by reference.
As used herein, “treating a disease or disorder” means reducing the frequency with which a symptom of the disease or disorder is experienced by a patient. Disease and disorder are used interchangeably herein.
As used herein, the term “treatment” or “treating” encompasses prophylaxis and/or therapy. Accordingly, the compositions and methods of the present invention are not limited
to therapeutic applications and can be used in prophylactic ones. Therefore “treating” or “treatment” of a state, disorder or condition includes: (i) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a subject that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition, (ii) inhibiting the state, disorder or condition, i.e., arresting or reducing the development of the disease or at least one clinical or subclinical symptom thereof, or (iii) relieving the disease, i.e. causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
Ranges: throughout this disclosure, various aspects of the invention can be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 2.7, 3, 4, 5, 5.3, and 6. This applies regardless of the breadth of the range.
Description
In one aspect, the invention provides a method of treating pain in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio between about 3: 1 and about 6: 1 CBD:THC. In various embodiments, the ratio is about 4: 1 or about 3 : 1 CBD:THC. In another aspect, the invention provides a method of treating anxiety in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio of about 4: 1 or about 3 : 1 CBD:THC. Without meaning to be limited by theory, compositions comprising specific ratios of CBD to THC show heightened efficacy in the treatment of pain (FIG. 3 A) and anxiety (FIG. 3B) relative to compositions comprising other ratios of these compounds.
In various embodiments, the pharmaceutical composition comprises 100 mg CBD + 30 mg THC. In various embodiments, the pharmaceutical composition comprises 40 mg CBD + 10 mg THC.
In various embodiments, subject is a mammal. In various embodiments, the subject is a human. A skilled person will recognize that a wide variety of dosage forms may be employed in various aspects and embodiments of the methods of the invention. In various embodiments the pharmaceutical composition is configured to be delivered as a nasal spray, orally, subcutaneously, parenterally, sublingually, as a lozenge or as a solid or liquid formulation.
In another aspect, the invention provides a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio of about 4: 1 or about 3: 1 CBD:THC. In various embodiments, the pharmaceutical composition comprises at least one pharmaceutically acceptable excipient.
EXPERIMENTAL EXAMPLES
The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.
Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples therefore, specifically point out the preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.
Example 1:
Eight 21-45-y ear-old men and women, who are recreational marijuana users but do not meet criteria for cannabis use disorder were recruited to complete six separate inpatient or outpatient laboratory sessions one week apart during which they were assigned to receive an acute dose of either 40 mg CBD, 100 mg CBD, 40/1 Omg each of CBD/THC, 40/20 mg of CBD/THC and 100/30 mg each CBD/THC or PLA, in a random, counter-balanced, double-blind,
cross-over design over a 7-week period. Sessions were completed one-week apart to allow for an adequate washout period between sessions.
The first study was directed towards assessing safety of the THC and CBD doses in healthy, recreational cannabis users. The key novel and surprising aspect of this study was the specific combinations of CBD+THC that were found to be significant in reducing pain and stress responses. Surprisingly, CBD alone (often thought of as pain reducing) was not as effective as a combination of CBD with low doses of THC in the 4: 1 and 3 : 1 range but not in the 2: 1 proportion range. So 100 CBD + 30 THC and the 40 CBD + 10 THC were significantly different that then 40 CBD + 20 THC and the 100 CBD alone and 40 CBD alone. This suggests that low amounts of THC may act synergistically to increase therapeutic efficacy for pain, but not at moderate (2:1) or higher amounts (1 : 1). The novel pain provocation experimental method allowed for detection of this effect within this first safety protocol assessment.
Example 2:
Study 2: Arm 1 : Adult men and women ages 21-68 (N=12) with chronic pain (not fully controlled by opioid pain medication), will be recruited and randomly assigned to receive the two doses of CBD40+THC10 (mg) and CBD100+THC30 (mg) dose (n=4 in each) or PL A (n=4) repeated dosing for 7 days. On day 1 and 6/7 of the 7-day dosing, subjects will complete laboratory sessions. Subjects cannot meet criteria for moderate/ severe cannabis use disorder or other addictive disorders.
Arm 2: Adult men and women ages 21-68 (N=12) with chronic pain and Opioid Use Disorder (OUD) (not fully controlled by opioid pain medication), will be recruited and randomly assigned to receive the two doses of CBD40+THC10 (mg) and CBD100+THC30 (mg) dose (n=4 in each) or PL A (n=4) repeated dosing for 7 days. On day 1 and Day 6/7 of the 7-day dosing, subjects will complete laboratory sessions. Subjects cannot meet criteria for moderate/severe other addictive disorders.
Arm 3: Adult men and women ages 21-68 (N=12) with chronic pain and Multiple Sclerosis (and pain not fully controlled by opioid pain medication), will be recruited and randomly assigned to receive the two doses of CBD40+THC10 and CBD100+THC30 dose (n=4 in each) or PLA (n=4) repeated dosing for 7 days. On day 1 and Day 6/7 of the 7-day dosing,
subjects will complete laboratory sessions. Subjects cannot meet criteria for moderate/severe cannabis use disorder or other addictive disorders.
In each case the combination of CBD and THC at the ratios taught herein will exhibit greater efficacy than these compounds administered alone or at other ratios.
Enumerated Embodiments
The following exemplary embodiments are provided, the numbering of which is not to be construed as designating levels.
Embodiment 1 provides a method of treating pain in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio between about 3 : 1 and about 6: 1 CBD:THC.
Embodiment 2 provides the method of embodiment 1, wherein the ratio is about 4: 1 or about 3: 1 CBD:THC.
Embodiment 3 provides the method of embodiments 1-2, wherein the pharmaceutical composition comprises 100 mg CBD + 30 mg THC.
Embodiment 4 provides the method of embodiments 1-3, wherein the pharmaceutical composition comprises 40 mg CBD + 10 mg THC.
Embodiment 5 provides the method of embodiments 1-4, wherein the subject is a human.
Embodiment 6 provides a method of treating anxiety in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio between about 3 : 1 and about 6: 1 CBD: THC.
Embodiment 7 provides a method of embodiment 6, wherein the ratio is about 4: 1 or about 3: 1 CBD: THC.
Embodiment 8 provides a method of embodiments 6-7, wherein the pharmaceutical composition comprises 100 mg CBD + 30 mg THC.
Embodiment 9 provides a method of embodiments 6-8, wherein the pharmaceutical composition comprises 40 mg CBD + 10 mg THC.
Embodiment 10 provides a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio of about 4: 1 or about 3: 1 CBD:THC.
Other Embodiments
The recitation of a listing of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or subcombination) of listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.
The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety. While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations.
Claims
1. A method of treating pain in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio between about 3: 1 and about 6: 1 CBD:THC.
2. The method according to claim 1, wherein the ratio is about 4: 1 or about 3 : 1 CBD:THC.
3. The method according to claim 1, wherein the pharmaceutical composition comprises 100 mg CBD + 30 mg THC.
4. The method according to claim 1, wherein the pharmaceutical composition comprises 40 mg CBD + 10 mg THC.
5. The method according to claim 1, wherein the subject is a human.
6. A method of treating anxiety in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio between about 3: 1 and about 6: 1 CBD: THC.
7. The method according to claim 6, wherein the ratio is about 4: 1 or about 3 : 1 CBD:THC.
8. The method according to claim 6, wherein the pharmaceutical composition comprises 100 mg CBD + 30 mg THC.
9. The method according to claim 6, wherein the pharmaceutical composition comprises 40 mg CBD + 10 mg THC.
10. A pharmaceutical composition comprising cannabidiol (CBD) and tetrahydrocannabinol (THC) at a ratio of about 4: 1 or about 3 : 1 CBD:THC.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163240702P | 2021-09-03 | 2021-09-03 | |
US63/240,702 | 2021-09-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023034568A1 true WO2023034568A1 (en) | 2023-03-09 |
Family
ID=85412885
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/042454 WO2023034568A1 (en) | 2021-09-03 | 2022-09-02 | Specific therapeutic medical marijuana doses for stress and pain |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023034568A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019237156A1 (en) * | 2018-06-15 | 2019-12-19 | CannPal Animal Therapeutics Limited | Cannabinoid composition and methods of treatment using the same |
WO2020006597A1 (en) * | 2018-07-03 | 2020-01-09 | Zelda Therapeutics Operations Pty Ltd | Cannabinoid composition and method for treating ptsd and/or anxiety |
WO2020183456A1 (en) * | 2019-03-10 | 2020-09-17 | Bol Pharma Ltd. | Cannabinoid combinations for treating chronic pain in dialysis patients |
WO2020220092A1 (en) * | 2019-05-01 | 2020-11-05 | Cannadol Pharmaceuticals | Compositions and methods for pain and anxiety relief |
WO2021077108A1 (en) * | 2019-10-18 | 2021-04-22 | The Children's Hospital Of Philadelphia | Method of treating autism |
-
2022
- 2022-09-02 WO PCT/US2022/042454 patent/WO2023034568A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019237156A1 (en) * | 2018-06-15 | 2019-12-19 | CannPal Animal Therapeutics Limited | Cannabinoid composition and methods of treatment using the same |
WO2020006597A1 (en) * | 2018-07-03 | 2020-01-09 | Zelda Therapeutics Operations Pty Ltd | Cannabinoid composition and method for treating ptsd and/or anxiety |
WO2020183456A1 (en) * | 2019-03-10 | 2020-09-17 | Bol Pharma Ltd. | Cannabinoid combinations for treating chronic pain in dialysis patients |
WO2020220092A1 (en) * | 2019-05-01 | 2020-11-05 | Cannadol Pharmaceuticals | Compositions and methods for pain and anxiety relief |
WO2021077108A1 (en) * | 2019-10-18 | 2021-04-22 | The Children's Hospital Of Philadelphia | Method of treating autism |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6381761B2 (en) | Method for treating bendamustine responsive symptoms in patients in need of reduced dose volume | |
US9107925B2 (en) | Sodium channel blocker for treatment of loss of superficial sensitivity | |
US20200101067A1 (en) | Use of levocetirizine and montelukast in the treatment of anaphylaxis | |
AU2011334617B2 (en) | Folic acid - Ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions | |
DE602004013035T2 (en) | SUSPENSION OF LOTEPREDNOL ETABONATE AND TOBRAMYCIN FOR TOPICAL OPHTHALMIC APPLICATION | |
JP2020534362A (en) | Synthetic percutaneous cannabidiol for the treatment of focal epilepsy in adults | |
US20210030678A1 (en) | Cannabinoid and cbd liposome formulations and uses thereof | |
EP2968309A2 (en) | Use of levocetirizine and montelukast in the treatment of vasculitis | |
JP2002534477A (en) | New use of melagatran | |
KR20120138229A (en) | Treating critically ill patients with intravenous ibuprofen | |
WO2023034568A1 (en) | Specific therapeutic medical marijuana doses for stress and pain | |
JP6051315B2 (en) | Use of pidothymod to treat psoriasis | |
US6693100B1 (en) | Pharmaceutical compositions for treating psoriasis | |
JPWO2020106927A5 (en) | ||
EP4180038A1 (en) | Use of composition in treatment of cerebral stroke | |
WO2024074515A1 (en) | Nitazoxanide for the treatment of hepatic impairment | |
Nakaki | Drugs that affect autonomic functions or the extrapyramidal system | |
WO2022152150A1 (en) | Application of cilostazol-containing composition in preparing drug for treating cerebrovascular disease | |
JP2022533394A (en) | How to transition patients being treated for pulmonary arterial hypertension to selexipag | |
RU2115428C1 (en) | Method of treatment of human with immunosuppression at sepsis | |
TW202214232A (en) | Medical use of a composition | |
htS Reserved | New Molecular Entities | |
Golshahi | Therapie mit Ketoconazol bei Chorioretinopathia Centralis Serosa: eine Pilotstudie | |
HRP20020201A2 (en) | Pharmaceutical compositions for treating psoriasis | |
JP2003089642A (en) | Pharmaceutical composition for treatment of erectile dysfunction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22865605 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |